Last fall, FDA safety officers began compiling a list of children possibly killed by COVID vaccines. Digging through ...

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ ...

A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% ...

Moderna's stock plunged on Thursday, startling investors. But the company remains one of this year’s hottest biotech ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

Pfizer (NYSE:PFE) signed a new research collaboration and license agreement with Enodia Therapeutics to develop Sec61 ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

Although ModernaMRNA initially established itself as a leading COVID-19 vaccine maker, the company is focused on broadening ...

The data were not bad — in fact, the outcome was better than many analysts had predicted. The problem was Cambridge-based ...